Pharmaceutical

CTX-310 by CRISPR Therapeutics for Hypertriglyceridemia: Likelihood of Approval

CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Hypertriglyceridemia.

Jul 6, 2024 - 04:00
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Hypertriglyceridemia.
Read the original article

Tags:

Previous Article

CTX-310 by CRISPR Therapeutics for Homozygous Familial Hypercholesterolemia (HoF...

Next Article

BNT-325 by Duality Biologics (Shanghai) for Metastatic Ovarian Cancer: Likelihoo...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Supreme Court maintains access to abortion pill mifepristone, at least for now

STAT+: Supreme Court maintains access to abortion pill ...

Apr 25, 2023

Opinion: STAT readers on burnt-out infectious disease doctors, 12-month prescriptions, and counting disabled Americans

Opinion: STAT readers on burnt-out infectious disease d...

Dec 3, 2023

Clues from mice could help explain why women face a higher risk of autoimmune disorders

Clues from mice could help explain why women face a hig...

Feb 1, 2024